Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront with ...
Zacks Investment Research on MSN
VKTX completes enrollment in phase I maintenance study of obesity drug
Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of ...
Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The biotech—which was launched into the ...
SAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company plans to accelerate the oral formulation of VK2735 following Phase 2 results and has also ...
11monon MSN
Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress
CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase ...
SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone beta receptor (TRβ) that possesses selectivity for liver tissue, as well as the beta receptor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback